#London #United Kingdom #EdgeCap Partners #ILIFE Consulting #Comac Medical Group

Comac Medical Group Expands with Strategic Acquisition of ILIFE Consulting

In a significant move for its European ambitions, Comac Medical Group, a leading player in the biotechnology landscape, has announced its acquisition of ILIFE Consulting, a renowned contract research organization (CRO) based in Paris, France. This strategic acquisition, supported by EdgeCap Partners, underscores Comac's commitment to enhancing its service offerings and establishing a robust presence across Europe, particularly in the domains of oncology and early-phase clinical trials.

Strengthening European Presence

Founded in 2013 by Marina Iché, ILIFE Consulting has garnered a strong reputation for its expertise in strategic consulting and the execution of complex clinical trials, particularly in the fields of oncology and rare diseases. This acquisition marks a pivotal step for Comac Medical Group in their journey to become a foremost partner for small and medium-sized pharmaceutical companies across Europe. The integration of ILIFE's capabilities will allow the group to augment its existing service portfolio—offering comprehensive solutions that include advanced biostatistics, data management, pharmacovigilance, and bioanalytical services, alongside Comac's own Early Phase Clinical Research Unit.

Marina Iché will continue to lead ILIFE as CEO, becoming a significant shareholder in the newly formed structure within the Comac umbrella. Her leadership is expected to help drive growth initiatives while maintaining the high standards and values that have positioned ILIFE as a trusted partner in the biotech ecosystem.

Shared Values and Vision

In her statements regarding the acquisition, Iché expressed enthusiasm about the collaboration with EdgeCap and Comac Medical Group. She emphasized a shared commitment to quality, innovation, and customer-centric services. Iché stated, "We mobilize our resources to ensure successful collaborations with our clients. By joining forces, we can leverage additional resources, broaden our service portfolio, and better serve clients throughout Europe and beyond."

Chris Smyth, the incoming CEO of Comac Medical Group, also commented on the strategic nature of this acquisition. He highlighted ILIFE’s established presence and expertise in France's biotech ecosystem, which significantly bolsters Comac’s capabilities. Smyth remarked, "I look forward to working closely with Marina and her team at ILIFE to create substantial value for our stakeholders and deliver excellence across our extensive geographical and therapeutic scope."

Expanding Leadership and Global Presence

This acquisition aligns with Comac Medical Group's recent leadership appointments and international expansion efforts. The company recently announced the appointment of Dr. Chris Smyth as the incoming CEO, effective September 1, 2025, along with Christian Buhlmann as Chief Commercial Officer and Peter Windisch as Chief Operating Officer, and Neil Ferguson as Chairman of the Board. These changes highlight a strategic restructuring aimed at enhancing Comac's operational efficiency and expanding its market reach.

About ILIFE Consulting

ILIFE Consulting, headquartered in Paris, offers specialized CRO services focused on early-phase oncology and biotechnological development. With extensive experience in tackling complex regulatory environments and optimizing trial processes, ILIFE provides personalized strategic support for biotechnology sponsors, enabling them to make reliable and cost-effective decisions.

With trusted relationships with over 20 biotech sponsors throughout Europe, ILIFE is dedicated to conducting high-impact studies that bring innovation closer to patients.

About Comac Medical Group

Based in London, Comac Medical Group stands as a premier pan-European full-service CRO aiming to be the preferred partner for global small and medium-sized biopharmaceutical firms. Operating in more than 30 countries, Comac offers a comprehensive range of drug development services across various therapeutic areas including oncology, rare diseases, dermatology, gastroenterology, and respiratory conditions. Their Clinical Research Unit (CRU) is recognized for its expertise, especially in Phase I studies, bioavailability, and bioequivalence, ensuring high-quality data generation and patient safety.

Conclusion

The acquisition of ILIFE Consulting significantly enhances Comac Medical Group’s capabilities and represents a strategic step to foster its growth across Europe. As the two organizations combine their strengths, they are well-positioned to make impactful contributions to the biotech industry, ultimately benefiting patients who seek innovative treatments and solutions.